0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

Raphael Dolin, MD; David A. Amato, PhD; Margaret A. Fischl, MD; Carla Pettinelli, MD, PhD; Mohan Beltangady, PhD; Song-heng Liou, MA; Michael J. Brown, PhD; Anne P. Cross, PhD; Martin S. Hirsch, MD; W. David Hardy, MD; Donna Mildvan, MD; Donald C. Blair, MD; William G. Powderly, MD; Michael F. Para, MD; Kenneth H. Fife, MD, PhD; Roy T. Steigbigel, MD; Laurie Smaldone, MD; Clyde S. Crumpacker, MD; Tim Cooley, MD; Ronald T. Mitsuyaso, MD; Ric John; Carsandra Sanders, RPA; Dinah Reitman, MPS; Ross Hewitt, MD; Richard C. Reichman, MD; Lawrence D. Gelb, MD; M. L. McGuire, BSN; Marcella Jones, RN, BSN; Judith L. Neidig, MS, RN; Beth Zwickl, RNC; Paula B. Hartman, RNC; Mary Elizabeth Roarke, BS, RN; Ruth Ann Burk, BS, RN; Jack Fuhrer, MD; Karen A. Somogyi, RN, BA; Kent Sepkowitz, MD; Edward E. Telzak, MD; Vincent J. McAuliffe, MD; Fred T. Valentine, MD; Margarita Vasquez, RN; Thomas C. Merigan, MD; David Katzenstein, MD; Jeffrey Fessell, MD; Diane V. Havlir, MD; Douglas D. Richman, MD; Stephen A. Spector, MD; James O. Kahn, MD; Linda Johnson, RN; Rebecca Coleman, PharmD; Monto Ho, MD; Deborah McMahon, MD; George Pazin, MD; Diana Antoniskis, MD; Bernard McNamara, MD; DeAnn Diamond, RN; Ann C. Collier, MD; Mary A. Paradise, ARNP; Anna Wald, MD; Ann DePaolis-Jones, RN, BSN; Keith Henry, MD; Hetty A. Waskin, MD; Newton E. Hyslop Jr, MD; David M. Mushatt, MD; James A. Zachary, MD; Roy Soeiro, MD; Carol Harris, MD; Barry Zingman, MD; Michael F. Giordano, MD; Sandra Sledz, RN; Henry W. Murray, MD; John T. Carey, MD; Traci L. Davis, RN; Brenda Bagby, MS; Harold A. Kessler, MD; Robert I. Murphy, MD; Robert E. Hirschtick, MD; Sarah H. Cheeseman, MD; Kwan Kew Lai, MD; Patrick G. Fairchild, MD; W. C. Ehmann, MD; J. J. Zurlo, MD; R. Millard, MD; Luigi Troiani, PA; Aline A. Heggen; Charles M. van der Horst, MD; George F. McKinley, MD; Michael H. Grieco, MD; Brenda R. Kolatch, MS; Jonathan C. Goldsmith, MD; Edward D. Gomperts, MD; Lin M. Woods, MN; Louis Grue, RN; Kate Mayjo, RN; Rebecca L. Becker, PA-C; D. T. Jayaweera, MD; Lisa Rolfe, RN, BSN; Joanne Cole, RN; John Jermano, RN, MPH
Arch Intern Med. 1995;155(9):961-974. doi:10.1001/archinte.1995.00430090111012.
Text Size: A A A
Published online

Background:  We conducted a trial to compare treatment with zidovudine or didanosine in patients with advanced human immunodeficiency virus type 1 (HIV-1) infection who had received little or no previous therapy with zidovudine.

Methods:  Six hundred seventeen patients with acquired immunodeficiency syndrome (AIDS), advanced AIDS-related complex (CD4 cell count, ≤0.30× 109/L [300/μL]), or asymptomatic HIV (CD4 cell count, ≤0.20× 109/L) received zidovudine, 500 mg/d of didanosine, or 750 mg/d of didanosine in a randomized, double-blind allocation, with cross-over to alternative medication after development of an end point or serious toxic effect. To be eligible, patients must have received either no or up to 16 weeks of zidovudine therapy before entry into the study. Primary end points were development of a new AIDS-defining event or death. Secondary clinical end points were new or recurrent AIDS-defining events, or death, and survival.

Results:  In the study as a whole, there were no differences in the relative risks (RRs) of the development of end points between treatment groups. However, there was a strong interaction between the relative efficacies of zidovudine and didanosine and previous experience with zidovudine. Among 380 patients with no previous zidovudine therapy, zidovudine was more effective than 750 mg/d of didanosine (RR, 1.43; 90% confidence interval [CI], 1.02 to 2.00), with a similar trend for zidovudine compared with 500 mg/d of didanosine (RR, 1.21; 90% CI, 0.86 to 1.71). However, among 118 patients with more than 8 weeks but no more than 16 weeks of previous zidovudine therapy, 500 mg/d of didanosine was more effective than zidovudine (RR, 0.48; 90% CI, 0.27 to 0.86); there was a similar trend for increased effectiveness of 750 mg/d of didanosine compared with zidovudine (RR, 0.61; 90% CI, 0.36 to 1.03). Among 119 patients who had some but no more than 8 weeks of previous zidovudine therapy, there were no significant differences among the treatment arms. Similar findings were noted in the analysis of the two secondary clinical end points. No significant differences were found in efficacy between the groups receiving 500 and 750 mg/d of didanosine. The major toxic effect associated with zidovudine was hematopoietic (granulocytopenia) and that associated with didanosine was pancreatitis (dosage, 750 mg/d).

Conclusions:  In patients with advanced HIV disease, zidovudine appears to be more effective than didanosine as initial therapy; however, some patients with advanced HIV disease may benefit from a change to didanosine therapy after as little as 8 to 16 weeks of therapy with zidovudine.(Arch Intern Med. 1995;155:961-974)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 59

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();